Rise and shine, everyone, another busy day is on the way. And a fine one it is, here on the Pharmalot campus, where the sun is shining, a breeze is wafting by, and our shortest person is, as usual, sleeping in. As for us, we are quaffing our mandatory cups of stimulation to prepare for the day ahead. As always, we invite you to join us. Remember, no prescription is required. So time to get cracking. Have a lovely day and, of course, do keep in touch …
Theresa May, who is about to become the next UK prime minister, says she wants to shield the country’s pharmaceutical industry from takeovers, Bloomberg News reports. The government nearly allowed AstraZeneca, “one of the jewels” in the crown of the British pharmaceutical industry, to be taken over by Pfizer, a company with a “track record of asset stripping and whose self-confessed attraction to the deal was to avoid tax,” May said.
Doubts over the UK’s ability to win future project grants mean some European Union partners are avoiding working with British researchers, the Guardian tells us. Elite UK universities are coming under pressure to abandon collaborations with European partners. There are instances in which British academics have been asked to leave EU-funded projects or to step down from leadership roles because they are considered a financial liability.
Eisai is threatening to reduce investment in the UK over access to cancer drugs, Pharma Times writes. Patients with thyroid cancer could be waiting three years for access to its Lenvima drug because it was not included in the Cancer Drugs Fund and cost-effectiveness guidelines will not be published until 2018. We “may be forced to consider its level of investment in the UK, because it is unacceptable that drugs which are manufactured in England cannot be provided to people in England, without delays of many years,” said Gary Hendler, who heads Eisai in Europe.
India’s Central Drugs Standard Control Organization has identified about 500 pharmaceutical manufacturing facilities with quality-control issues, the Economic Times lets us know. The government hopes that new inspections will cut hygiene, personnel training, and other quality-related issues by up to 90 percent. Inspections of up to 250 facilities have already begun in the first phase on a risk priority-basis.
The US Food and Drug Administration approved Shire eye drops for treating dry-eye disease, the first treatment for the ailment to be approved in more than a decade, Bloomberg News tells us. Known as Xiidra, the medicine is forecast to become a blockbuster seller by 2022, with sales of just over $1 billion. A rival product called Restasis from Allergan causes eyes to tear.
Nichi-Iko Pharmaceutical agreed to pay $736 million for Sagent Pharmaceuticals in a bid to boost its generic and biosimilars efforts, Investor’s Business Daily says.
Cipla plans to invest about $90 million to build South Africa’s first biotech manufacturing plant for biosimilars, according to BioSpectrum.
The European Medicines Agency told stakeholders that the agency’s operations will continue as usual and its work is not affected by the outcome of the Brexit vote, PMLive reports.
Astellas plans to conduct clinical trials of a vaccine for serious diarrhea diseases that does not need to be refrigerated or injected and is produced in transgenic rice plants, InPharma Technologist writes.